P
Peter J. Barnes
Researcher at National Institutes of Health
Publications - 1554
Citations - 177909
Peter J. Barnes is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Asthma & COPD. The author has an hindex of 194, co-authored 1530 publications receiving 166618 citations. Previous affiliations of Peter J. Barnes include University of Nebraska Medical Center & Novartis.
Papers
More filters
Journal ArticleDOI
Characterization of muscarinic receptor subtypes in pig airways: radioligand binding and northern blotting studies.
TL;DR: The result suggests that the dominant muscarinic receptor in pig airways is of the M2 subtype, and the high- and the low-affinity [3H]telenzepine binding sites displayed the pharmacological profile of M1 and M2 receptors, respectively.
Journal ArticleDOI
Phosphodiesterase 4 in macrophages: relationship between cAMP accumulation, suppression of cAMP hydrolysis and inhibition of [3H]R-(-)-rolipram binding by selective inhibitors.
TL;DR: Results support the concept that PDE4 can exist in different conformational states and provide evidence that the cAMP content in macrophages is regulated primarily by a conformer of PDE3 for which rolipram has nanomolar affinity.
Journal ArticleDOI
Pharmacogenomics and targeted therapy of cancer: Focusing on non-small cell lung cancer.
Seyyed Mortaza Haghgoo,Abdolamir Allameh,Esmaeil Mortaz,Johan Garssen,Gert Folkerts,Peter J. Barnes,Ian M. Adcock +6 more
TL;DR: Combinations of kinase inhibitors or potentially the targeting of cancer stem cells may further increase the success of pharmacogenomics in treating patients with lung cancer.
Journal ArticleDOI
Stimulus-specific inhibition of IL-5 by cAMP-elevating agents and IL-10 reveals differential mechanisms of action.
TL;DR: The potential for downregulating Th2 responses by cAMP-elevating agents or IL-10 is demonstrated and a significant role for posttranscriptional mechanisms in the inhibition by IL- 10 is suggested.
Journal ArticleDOI
Novel therapy for COPD.
TL;DR: The patient with COPD is often overlooked compared to their asthmatic counterpart, who benefit from an urgent need to identify novel targets and better therapy, which requires reliable Phase II decision making before entering large scale Phase III studies.